DANVERS, Mass., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Abiomed,Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical updates on its Symphony™ device, including the second successful human use of Symphony in Canada. The procedure was performed by Renzo Cecere, M.D., Director of the Mechanical Assist Program and Surgical Director of the Heart Failure and Heart Transplant Program at the McGill University Health Centre (MUHC) in Montreal, Quebec.
The Symphony device is a minimally invasive implantable heart pump designed to slow the progression of heart failure and help the heart remodel. The first two patient experiences have been positive and informative for the future promise of the therapy. In both patients, an improvement was immediately demonstrated in overall hemodynamics and physical functionality based on support via the subclavian artery through a non sternotomy, "pacemaker-like" implantation technique.
Both patients were implanted at the MUHC by Dr. Renzo Cecere. This newest patient received Symphony in September 2012 and was successfully explanted as planned after 28 days of therapy."We were extremely pleased with the patient's overall improvement and the Symphony's performance over 28 days of continuous therapy," said Dr. Cecere. "We look forward to the ongoing development of this program with additional patients in the coming months." Additionally, Abiomed recently received ANSM (Agence Nationale de Sécurité du Médicament) approval in France, enabling the use of Symphony in clinical trials. Currently, a select number of hospitals in France are training to implant the Symphony device in clinical investigations. "We are encouraged to learn of the second patient's results with Symphony and believe this unique implantable heart pump will offer a minimally invasive, cost-effective approach to improve hemodynamics for these types of chronic heart failure patients. We look forward to continued clinical progress in Canada and France," said Michael R. Minogue, Chairman, President, and Chief Executive Officer of Abiomed.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV